Phase III read­outs spell dis­as­ter for Genen­tech’s lead IBD drug

Roche had big plans for etrolizum­ab. Eye­ing a hy­per-com­pet­i­tive IBD and Crohn’s mar­ket where they have not his­tor­i­cal­ly been a play­er, the com­pa­ny rolled out 8 dif­fer­ent Phase III tri­als, test­ing the an­ti­body for two dif­fer­ent us­es across a range of dif­fer­ent pa­tient groups.

On Mon­day, Roche re­leased re­sults for 4 of those stud­ies, and they mark a de­cid­ed set­back for both the Swiss phar­ma and their biotech sub Genen­tech, po­ten­tial­ly spelling an end to a drug they put over half-a-decade and mil­lions of dol­lars be­hind.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.